- Home
- DSGN vs ETX Comparison
DSGN vs ETX Comparison
Compare DSGN & ETX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- ETX
- Stock Information
- Founded
- DSGN 2017
- ETX 2005
- Country
- DSGN United States
- ETX United States
- Employees
- DSGN N/A
- ETX N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- ETX
- Sector
- DSGN Health Care
- ETX
- Exchange
- DSGN Nasdaq
- ETX NYSE
- Market Cap
- DSGN 208.9M
- ETX 196.3M
- IPO Year
- DSGN 2021
- ETX N/A
- Fundamental
- Price
- DSGN $3.35
- ETX $18.01
- Analyst Decision
- DSGN Hold
- ETX
- Analyst Count
- DSGN 1
- ETX 0
- Target Price
- DSGN $4.00
- ETX N/A
- AVG Volume (30 Days)
- DSGN 89.5K
- ETX 32.7K
- Earning Date
- DSGN 08-04-2025
- ETX 01-01-0001
- Dividend Yield
- DSGN N/A
- ETX 4.20%
- EPS Growth
- DSGN N/A
- ETX N/A
- EPS
- DSGN N/A
- ETX N/A
- Revenue
- DSGN N/A
- ETX N/A
- Revenue This Year
- DSGN N/A
- ETX N/A
- Revenue Next Year
- DSGN N/A
- ETX N/A
- P/E Ratio
- DSGN N/A
- ETX N/A
- Revenue Growth
- DSGN N/A
- ETX N/A
- 52 Week Low
- DSGN $2.60
- ETX $16.36
- 52 Week High
- DSGN $7.77
- ETX $18.60
- Technical
- Relative Strength Index (RSI)
- DSGN 36.07
- ETX 43.21
- Support Level
- DSGN $3.65
- ETX $17.97
- Resistance Level
- DSGN $4.21
- ETX $18.30
- Average True Range (ATR)
- DSGN 0.22
- ETX 0.12
- MACD
- DSGN -0.06
- ETX -0.02
- Stochastic Oscillator
- DSGN 0.00
- ETX 12.12
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About ETX EATON VANCE MUNICIPAL INCOME 2028
Eaton Vance Municipal Income 2028 Term Trust is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The fund invests in various sectors such as a bond bank, education, housing, electric utilities, transportation, and others.